ArcaScience
About
What is ArcaScience's revenue?
StartupHub estimates ArcaScience's annual revenue at $1.0M (range $553K to $1.6M, 27% confidence), based on comparable companies in the sector.
What is ArcaScience's valuation?
StartupHub estimates ArcaScience's effective valuation at $58.1M (range $40.0M to $96.0M, 18% confidence), based on comparable companies in the sector.
How much funding has ArcaScience raised?
ArcaScience has raised a total of $16M in funding. The most recent round on record is Seed.
Where is ArcaScience headquartered?
ArcaScience is headquartered in San Francisco, United States.
When was ArcaScience founded?
ArcaScience was founded in 2022.
What industry does ArcaScience operate in?
ArcaScience operates in AI-Driven Drug Discovery, Biotech, HealthTech, Foundation Model, Generative AI, AI Research.
What is ArcaScience's current status?
ArcaScience's current operating status is: Inactive.
An AI-powered platform for cancer patients and survivors in Asia to navigate care and understand their diagnosis.
AI-powered platform for streamlining technical records, sample boundaries, and review processes.
AI-powered platform accelerating biological research and drug discovery.
AI-powered platform for personalized dental care and smile design.
A trusted, Apple-quality document assistant that transforms complex paperwork, medical reports, and legal notices into simple, actionable plain language for everyday life.
AI-driven platform for accelerating the discovery and design of novel toxins and therapeutic molecules.
Less keyboard, more patient. The clinical copilot that returns the joy of medicine to your practice.
Apimedtech is developing a novel platform for personalized medicine, leveraging AI and advanced analytics to improve patient outcomes.
An entrant is a company tagged AI-Driven Drug Discovery whose domain was first registered in the window, counted from registry records in the StartupHub directory. Registry detection runs two to three weeks behind registration, so recent weeks are a floor.
No comments yet. Be the first to share your take.